IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: Owing to its selective cytotoxicity for cells expressing IL-2 receptor α (IL2RA, best known as CD25), denileukin diftitox has been approved by the US FDA and EMA for the treatment of CD25+ cutaneous T-cell lymphoma in the early 2000s [494].